CORRECTION

Correction to: A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine

Yara Ruiz Garcia · Véronique Abitbol · Michele Pellegrini ·
Rafik Bekkat-Berkani · Lamine Soumahoro

Published online: November 27, 2021
© The Author(s) 2021

Correction to: Infect Dis Ther
<https://doi.org/10.1007/s40121-021-00519-2>

In the original publication of the article, figure 2 and the corresponding video were erroneously published. Fig. 2 and the video have now been corrected in the paper.

The original article can be found online at <https://doi.org/10.1007/s40121-021-00519-2>.

This article is published with digital features, including a plain language summary and video, to facilitate understanding of the article. To view digital features for this article go to <https://doi.org/10.6084/m9.figshare.14980980>.

Y. Ruiz Garcia · R. Bekkat-Berkani
Global Medical Affairs, GSK, Rockville, MD, USA

V. Abitbol
Global Medical Affairs, GSK, Rueil-Malmaison,
France

M. Pellegrini
Global Clinical Research and Development, GSK,
Siena, Italy

L. Soumahoro (✉)
Global Medical Affairs, GSK, GSK Vaccines, Avenue
Fleming 20, 1300 Wavre, Belgium
e-mail: lamine.m.soumahoro@gsk.com

	Infants & toddlers	Children	Adolescents	Adults	Pregnant* women
	2–24 months	>2–10 years	11–18 years	>18 years	14–22 years
Safety	Well tolerated, including as a booster dose and when co-administered				Frequency of birth outcomes similar to those observed in the general population
Immunogenicity	Immunogenic as primary vaccination and when co-administered, robust booster response				
Potential co-administration	Routine vaccinations HAV, HBV, Hib, IPV, DTaP, PCV7, PCV13, Rotavirus, MMR, V, MMRV Vaccines against MenB 4CMenB		Routine vaccinations Tdap, HPV	Routine vaccinations Tdap, Td, HPV, PCV13 Vaccines against MenB 4CMenB Traveler vaccines Yellow fever, Rabies, Typhoid fever, Japanese encephalitis, HAV, HBV	
Carriage	Decrease of nasopharyngeal carriage for serogroups C, W and Y				
Real-world impact	Reduction of IMD occurrence in a high-exposure group from South Korea				

Fig. 2 Summary of the MenACWY-CRM experience accrued during the first decade since its licensure. For more details, see video file 1 in the online/HTML version of the manuscript or follow the digital features link. *MenACWY-CRM inadvertently administered within 28 days prior to conception or during pregnancy. MenACWY-CRM is not indicated in pregnant women. MenACWY-CRM quadrivalent meningococcal vaccine against serogroups A, C, W and Y, conjugated to the nontoxic mutant of diphtheria toxin, HAV hepatitis A vaccine, HBV hepatitis B vaccine, Hib *Haemophilus influenzae* type b vaccine, IPV inactivated poliomyelitis

vaccine, DTaP combined diphtheria, tetanus, acellular pertussis, PCV7 7-valent pneumococcal conjugate vaccine, PCV13 13-valent pneumococcal conjugate vaccine, Rotavirus rotavirus vaccine, MMR measles-mumps-rubella vaccine, V varicella vaccine, MMRV measles-mumps-rubella-varicella vaccine, Tdap tetanus-diphtheria-acellular pertussis vaccine, Td tetanus-diphtheria toxoid, HPV human papillomavirus vaccine, MenB *Neisseria meningitidis* serogroup B, 4CMenB multicomponent vaccine against meningococcal serogroup B, IMD invasive meningococcal disease

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and

indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence,

visit <http://creativecommons.org/licenses/by-nc/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.